FDA Approves ' Game Changer ' Semaglutide for Weight Loss FDA Approves ' Game Changer ' Semaglutide for Weight Loss

UPDATED // Based on the STEP clinical trial results, the FDA has approved a 2.4 mg/week subcutaneous dose of the GLP-1 receptor agonist semaglutide (Wegovy, Novo Nordisk) for weight loss.FDA Approvals
Source: Medscape Pediatrics Headlines - Category: Pediatrics Tags: Diabetes & Endocrinology News Alert Source Type: news